Latigo’s $150 million fundraise shows potential gains from pain as early-stage non-opioid pipeline grows
Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is anything to go by.
The massive series B financing - led by Blue Owl Capital - marks the group’s second mega round since coming out of stealth mode with a $135 million series A raise just 14 months ago.
Latigo’s venture haul comes hot on the heels of the approval of Vertex’s Journavx (suzetrigine), the first non-opioid pain drug green lighted by the Food and Drug Administration (FDA0. Like Journavx, Latigo’s lead product LTG-001, and follow up candidate LTG-305, are an ion channel blockers using the Nav1.8 inhibitor pathway. Ion channel blockers selectively target peripheral nerves, rather than the brain avoiding the potential for addiction.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze